AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Max-interacting protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for protein-protein interfaces.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes extensive molecular simulations of the target protein alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that considers conformational mobility in both free and complex states. Potential binding pockets are examined on the protein-protein interaction interface and in distant allosteric sites to cover all possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P50539

UPID:

MXI1_HUMAN

Alternative names:

Class C basic helix-loop-helix protein 11

Alternative UPACC:

P50539; B1ANN7; D3DR25; D3DRA9; Q15887; Q6FHW2; Q96E53

Background:

Max-interacting protein 1, also known as Class C basic helix-loop-helix protein 11, plays a crucial role in cellular processes by acting as a transcriptional repressor. It forms a complex with MAX, recognizing the core sequence 5'-CAC[GA]TG-3', thereby antagonizing MYC transcriptional activity. This interaction is pivotal in regulating gene expression and maintaining cellular homeostasis.

Therapeutic significance:

Given its involvement in prostate cancer, where disease susceptibility is linked to gene variants, Max-interacting protein 1 represents a promising target for therapeutic intervention. Understanding its role in cancer biology could lead to the development of novel strategies aimed at modulating its activity, potentially offering new avenues for treatment of prostate cancer and enhancing patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.